Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
(Sprache: Englisch)
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and...
Voraussichtlich lieferbar in 3 Tag(en)
versandkostenfrei
Buch (Kartoniert)
164.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways “
Klappentext zu „Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways “
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.Inhaltsverzeichnis zu „Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways “
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.Autoren-Porträt
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.
Bibliographische Angaben
- 2019, Softcover reprint of the original 1st ed. 2018, XX, 242 Seiten, 242 farbige Abbildungen, Maße: 15,5 x 23,5 cm, Kartoniert (TB), Englisch
- Herausgegeben: Yosef Yarden, Moshe Elkabets
- Verlag: Springer, Berlin
- ISBN-10: 3030098176
- ISBN-13: 9783030098179
Sprache:
Englisch
Kommentar zu "Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways"
Schreiben Sie einen Kommentar zu "Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways".
Kommentar verfassen